Ashwani Verma
Stock Analyst at UBS
(2.84)
# 1,774
Out of 4,947 analysts
77
Total ratings
40.74%
Success rate
0.13%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $385 → $415 | $312.13 | +32.96% | 6 | Aug 13, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $32 → $36 | $24.92 | +44.46% | 5 | Aug 8, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $43 → $38 | $38.65 | -1.68% | 4 | Jul 30, 2025 | |
| IMVT Immunovant | Maintains: Neutral | $17 → $18 | $15.20 | +18.42% | 1 | Jul 28, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $152 → $174 | $131.31 | +32.51% | 9 | Jul 9, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $60 → $54 | $37.60 | +43.62% | 3 | Jul 2, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $24 → $23 | $17.66 | +30.24% | 9 | Jun 26, 2025 | |
| ALKS Alkermes | Upgrades: Buy | $33 → $42 | $28.26 | +48.62% | 5 | Jun 17, 2025 | |
| INCY Incyte | Maintains: Neutral | $61 | $86.57 | -29.54% | 1 | Jun 3, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $47 → $41 | $38.70 | +5.94% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $48 | $36.51 | +31.47% | 2 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.03 | +2.44% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $179 | $117.34 | +52.55% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $14 | $13.50 | +3.70% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $71.95 | +58.45% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $14.48 | +272.93% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $108.76 | -3.46% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $36.43 | -23.13% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $91.38 | -92.34% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $10.76 | +11.52% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.55 | +2,603.68% | 1 | Oct 11, 2022 |
United Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $385 → $415
Current: $312.13
Upside: +32.96%
ACADIA Pharmaceuticals
Aug 8, 2025
Maintains: Buy
Price Target: $32 → $36
Current: $24.92
Upside: +44.46%
Exelixis
Jul 30, 2025
Maintains: Neutral
Price Target: $43 → $38
Current: $38.65
Upside: -1.68%
Immunovant
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $15.20
Upside: +18.42%
Neurocrine Biosciences
Jul 9, 2025
Maintains: Buy
Price Target: $152 → $174
Current: $131.31
Upside: +32.51%
Legend Biotech
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $37.60
Upside: +43.62%
Teva Pharmaceutical Industries
Jun 26, 2025
Maintains: Buy
Price Target: $24 → $23
Current: $17.66
Upside: +30.24%
Alkermes
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $28.26
Upside: +48.62%
Incyte
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $86.57
Upside: -29.54%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $38.70
Upside: +5.94%
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $36.51
Upside: +31.47%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.03
Upside: +2.44%
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $117.34
Upside: +52.55%
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $13.50
Upside: +3.70%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $71.95
Upside: +58.45%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $14.48
Upside: +272.93%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $108.76
Upside: -3.46%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $36.43
Upside: -23.13%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $91.38
Upside: -92.34%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $10.76
Upside: +11.52%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.55
Upside: +2,603.68%